-
Mashup Score: 3Oriel - 3 month(s) ago
Published vacancies that are available for applicants to apply to. This includes key information suchs as the training programme(s), post type(s), advert information and duration.
Source: www.oriel.nhs.ukCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28AACR Annual Meeting 2024 - 1 year(s) ago
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Source: www.aacr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28AACR Annual Meeting 2024 - 1 year(s) ago
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Source: www.aacr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28AACR Annual Meeting 2024 - 1 year(s) ago
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Source: www.aacr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25
Mismatch repair-deficient (MMRd) colorectal cancers (CRCs) have high mutation burdens, which make these tumours immunogenic and many respond to immune checkpoint inhibitors. The MMRd hypermutator phe…
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4AACR Annual Meeting 2024 - 2 year(s) ago
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Source: www.aacr.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3items - Jobs - 2 year(s) ago
Department: Barts Cancer InstituteSalary: £36,348 – £42,592 per annum (Grade 4)Reference: QMUL31987Location: Charterhouse SquareDate posted: 14 February 2023Closing date: 27 March 2023Further details and applyOverviewAbout the Role Applications are sought for an experienced Post Doc who will lead a new gastro-oesophageal cancer research study. The project aims to develop more effective…
Source: www.qmul.ac.ukCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0γδ T cells are effectors of immunotherapy in cancers with HLA class I defects - Nature - 2 year(s) ago
γδ T cells contribute to the response to immune checkpoint blockade treatment in patients with HLA-class-I-negative DNA mismatch repair-deficient colon cancers. .
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer - 3 year(s) ago
Woolston et al. show that in metastatic colorectal cancer cetuximab resistance can be conferred by genetic mechanisms, such as NF1 loss or RAS/RAF alterations, or by transcriptomic changes that induce a stroma-rich phenotype. They also provide a rationale for combining cetuximab with immunotherapy.
Source: Cancer CellCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0@marcogerlinger's Profile / Post. - 3 year(s) ago
Marco Gerlinger@marcogerlingerOncologist and scientist1 Posts3 Following0 FollowersMedical Oncologist and Clinician Scientist at Barts Cancer Institute and St Bartholomew’s Hospital. Cancer therapeutics, immunotherapy and biomarkers – all in the context of Darwinian Evolution. Director of GI Cancer Research at St Barts Hospital
Source: post.newsCategories: Hem/Oncs, Latest HeadlinesTweet
🔥Just opened: 4 year CLINICAL LECTURERSHIP position in HISTOPATHOLOGY @NHSBartsHealth and my lab @QMBCI in London: for ST3/4 registrars who already hold a PhD/MD. Great opportunity for a deep dive into the immunobiology of MMRd cancer. Deadline 11/04 10am https://t.co/MDV9s1DBSB